Skip to content


Aimovig (erenumab) is an antibody pharmaceutical. Erenumab was first approved as Aimovig on 2018-05-17. It has been approved in Europe to treat migraine disorders. It is known to target calcitonin gene-related peptide type 1 receptor.
Trade Name Aimovig
Common Name Erenumab
Indication migraine disorders
Drug Class Monoclonal antibodies: fully human, neural indications
Get full access now